Nightstar Therapeutics (Nightstar Therapeutics) Cash Flow from Financing : $77.16 Mil (TTM As of Mar. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Nightstar Therapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2019, Nightstar Therapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Nightstar Therapeutics spent $0.00 Mil on financial activities for the three months ended in Mar. 2019.

Nightstar Therapeutics Cash Flow from Financing Historical Data

The historical data trend for Nightstar Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nightstar Therapeutics Cash Flow from Financing Chart

Nightstar Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Cash Flow from Financing

13.96

11.32

141.09

77.16

Nightstar Therapeutics Quarterly Data
	Dec15	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Cash Flow from Financing	Get a 7-Day Free Trial						-	-	-	77.16	-

Nightstar Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Nightstar Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2018 is calculated as:

	Cash Flow from Financing		(A: Dec. 2018 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	77.164	+	0	+	0	+	0	+	0	+	0
=	77.16

Nightstar Therapeutics's Cash from Financing for the quarter that ended in Mar. 2019 is:

	Cash Flow from Financing		(Q: Mar. 2019 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $77.16 Mil.

Nightstar Therapeutics (NAS:NITE) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Nightstar Therapeutics's issuance of stock for the three months ended in Mar. 2019 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Nightstar Therapeutics's repurchase of stock for the three months ended in Mar. 2019 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Nightstar Therapeutics's net issuance of debt for the three months ended in Mar. 2019 was $0.00 Mil. Nightstar Therapeutics received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Nightstar Therapeutics's net issuance of preferred for the three months ended in Mar. 2019 was $0.00 Mil. Nightstar Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Nightstar Therapeutics's cash flow for dividends for the three months ended in Mar. 2019 was $0.00 Mil. Nightstar Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Nightstar Therapeutics's other financing for the three months ended in Mar. 2019 was $0.00 Mil. Nightstar Therapeutics received $0.00 Mil on other financial activities.

Nightstar Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Nightstar Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Nightstar Therapeutics (Nightstar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nightstar Therapeutics PLC (NAS:NITE) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Euston Road, London, GBR, NW1 2BE

Website

http://www.nightstartx.com

Nightstar Therapeutics Ltd is a clinical-stage gene therapy company. It is focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases. The company's retinal gene therapy product candidate, NSR-REP1, is being developed for the treatment of choroideremia, a rare, degenerative, X-linked genetic retinal disorder primarily affecting males that is caused by a mutation in the CHM gene.

Executives

Nea 15 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Gregory Scott Robinson	officer: Chief Scientific Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
James G Mcarthur	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram	officer: Chief Financial Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Tuyen Ong	officer: Chief Development Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Paula K Cobb	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott M Whitcup	director	2525 DUPONT DRIVE, IRVINE CA 92612
Scott D Sandell	10 percent owner
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett	10 percent owner